Targeting Therapy of Alzheimer’s and Related Neurodegenerative Diseases

Kongressthemen
Alzheimer’s disease (AD) is the most common age-dependent neurodegenerative disease, which affects over 5 million people in the US and over 35 million people worldwide. Currently, only four drugs are approved for alleviating symptoms in AD patients, and no new therapy has been approved for AD since 2003.

Kongressorganizer (PCO)
Fusion Conferences

Anmerkungen
Speakers: Riqiang Yan (Cleveland Clinic Lerner Research Institute), Peter St George-Hyslop (University of Toronto), Don Cleveland (University of California at San Diego), David Holtzman (Washington University) and many more.

https://go.evvnt.com/156680-1

Conference Manager